• Telmisartan 80 mg daily vs placebo.
  • Population- ACE inhibitor intolerant patients with either
    • Coronary artery, cerebrovascular or peripheral vascular disease or
    • Diabetes with end organ damage.
  • Primary endpoint of cardiovascular death, MI, stroke, or hospitalization for heart failure did not decrease.
  • Lower incidence of MI + stroke + cardiovascular death (same combination as in HOPE).
  • Lower incidence of myocardial infarction.
  • Did not reduce heart failure.
  • Lancet2008;372:1174-83.